【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品 (Melitracen)為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人。

It is an effective adjunctive anticonvulsant for the treatment of multidrug-refractory complex partial seizures in adults. It is also effective in resistant partial seizures and infantile spasms in children and adolescents.

Vigabatrin, an irreversible inhibitor of gamma-aminobutyric acid transaminase (GABA-T), is an anticonvulsant.

Rapidly absorbed following oral administration. Not protein bound. Almost no metabolic transformation. Does not induce the hepatic cytochrome P450 system. Eliminated primarily through renal excretion as unchanged drugs (80%). Half life - Neonates, 50 mg/kg = 7.5 ± 2.1 hours (due to reduced renal function); Infants = 5.7 hours; Adults = 7.5 hours; Elderly = 12 - 13 hours.

Hypersensitivity to vigabatrin.

C

Vigabatrin distributes into milk, probably in small amounts. Because of the potential for serious adverse reactions to vigabatrin in nursing infant, the manufacturer states that a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

Headache, ataxia, irritablility, behavior changes, anxiety, gastrointestinal disturbance, weight gain, and acute psychosis; psychosis has occurred upon abrupt withdrawal of vigabatrin.

Adults:for add-on therapy 2-3 g/day, increase to 4 g daily if necessary Children: 1-2 g/day.